MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470
Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular
hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470
0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for
up to 12 months.